Comparing lower vs standard dose of an antibiotic to prevent lung infection after kidney transplant
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This study compares a lower dose versus the standard dose of the antibiotic TMP-SMX (Bactrim) to prevent a type of lung infection (Pneumocystis pneumonia) after a kidney transplant. If you are eligible, you will receive either a lower or standard dose to see which works just as well with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have received your first kidney transplant.
- Your kidney function must be stable, with a creatinine clearance (a measure of how well your kidneys filter waste) above 30 ml/min.
- You must be willing to sign a consent form and cooperate with the study team.
- You cannot have HIV, a history of allergy to the antibiotic TMP-SMX (Bactrim, Septra), a previous Pneumocystis pneumonia infection, or certain other health conditions like G6PD deficiency, active infections, or immune system disorders.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether older kidney transplant recipients can safely reduce their immunosuppression medications using a special monitoring tool called Trugraf. If you are over 55, have had a stable transplant, and want to possibly lower your medications, this study may be for you.
This trial tests how long kidney transplant patients should take a common antibiotic (sulfamethoxazole) to prevent a lung infection called PJP. You may join if you are between 18 and 70 and have had a kidney transplant.
This study looks at whether continuing an antibiotic called TMP-SMX (Bactrim) for longer helps prevent urinary tract infections after a kidney transplant. If you've already taken it safely for 6 months, you may qualify to continue it for another 6 months or stop, to see which is better.
This study tests whether giving an antibiotic after a kidney transplant can prevent bloodstream infections. Participants who have bacteria in their urine in the first month after transplant may be eligible.
This Phase 3 study tests whether low-dose trimethoprim-sulfamethoxazole (also called TMP-SMX) can treat Pneumocystis pneumonia (PCP) in people with weakened immune systems. It may help improve treatment while reducing side effects compared with standard dosing.
This study looks at giving anti-infection medications (antibiotics) in a more personalized way soon after a kidney transplant. By carefully adjusting the dose, doctors hope to prevent infections while keeping the new kidney safe.
Hear when a new Kidney Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.